Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 3/19/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Thomas X. Neenan PhD

Wrong Dr. Thomas X. Neenan PhD?

Chief Scientific Officer

Company Description: Sun BioPharma, Inc. was founded in 2011 by former executives of SunPharm Corp. which was acquired by GelTex Pharmaceuticals, known for developing small-molecule...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • Ph.D.
  • B.Sc , Chemistry and Math
    University College Dublin
  • Ph.D , Synthetic Chemistry
    Penn State University
  • BS , Chemistry and Math
    University College Dublin
14 Total References
Web References
Thomas X. Neenan, Ph.D., ...
www.sunbiopharma.com, 19 Mar 2015 [cached]
Thomas X. Neenan, Ph.D., Co-Founder, Chief Scientific Officer and Member of the Board of Directors. Dr. Neenan is an entrepreneur and scientist with extensive chemistry and business development executive experience with AT&T Bell Labs, Geltex, Genzyme, Trine Pharma, Warwick Effect Polymers, Gelesis and Proxy Biomedical. Dr. Neenan most recently served as Founder and Chief Technology Officer of Sideris Pharmaceuticals Inc, raising $32M in equity financing in 2013 Dr. Neenan holds a B.Sc (Hons) in Chemistry and Math from the University College Dublin in Ireland, a Ph.D in Synthetic Chemistry from Penn State University, and post-doctoral studies in chemistry at Harvard University. Dr. Neenan also brings a wealth of knowledge to the Company on drug manufacture and was instrumental in improving the synthetic process for SUN-101. He is the author of approximately 60 publications in the fields of chemistry and materials sciences and holds approximately 40 US and international patents.
Sun BioPharma | Pancreatic Cancer Therapy Research
www.sunbiopharma.com, 19 Mar 2015 [cached]
Thomas Neenan, Ph.D.
...
Thomas Neenan, Ph.D. Chief Scientific Officer Read More
Thomas X. Neenan, ...
www.siderispharma.com, 14 Nov 2014 [cached]
Thomas X. Neenan, PhD Founder and Chief Technology Officer
...
Thomas Neenan Dr. Neenan founded Sideris in 2012 and assumed the role of CTO in 2013. Prior to Sideris, Dr. Neenan served in senior management roles at Viscus Biologics LLC, Proxy Biomedical (Galway, Ireland), Warwick Effect Polymers (Coventry, UK) and Trine Pharmaceuticals. Previously, he served as Vice-President, Business Operations, for Genzyme Drug Discovery and Development. Dr. Neenan began his career at AT&T Bell Laboratories, Murray Hill, N.J., where he served as a Principal Investigator. Dr. Neenan holds a B.Sc (Hons) in chemistry from University College Dublin of the National University of Ireland. He received a Ph.D. in inorganic and materials chemistry from The Pennsylvania State University, and was a Fellow at Harvard University with Prof. George Whitesides. He is the author of over 60 publications and holds over 40 US and international patents. Dr. Neenan serves on the Board of Sun BioPharma Inc., a pancreatic oncology company.
Thomas X. Neenan ...
kslsfund.com, 24 Sept 2014 [cached]
Thomas X. Neenan Ph.D.
Dr. Neenan is a Boston based entrepreneur whose most recent venture was as Founder and CTO of Sideris Pharmaceuticals Inc., a developer of novel chelators for the treatment of diseases of iron overload. Sideris raised $32M in equity financing and completed an option deal worth up to $300M with Novartis Pharmaceuticals in Oct. 2013. Prior to Sideris, Dr. Neenan served in founder or senior management role at several materials and polymer focused companies including Viscus Biologics LLC (xenografts), Proxy Biomedical (Galway, Ireland) (polymeric surgical materials), Warwick Effect Polymers (Coventry, UK) (controlled free radical polymerization for consumer and biomedical applications) and Trine Pharmaceuticals (gastrointestinal drugs). Previously, Dr. Neenan held positions of increasing responsibility, including Vice-President of New Technology Development at Geltex Pharmaceuticals, a polymer drug company acquired by Genzyme for $1.1B. Dr. Neenan holds a B.Sc (Hons) from University College Dublin. He received his Ph.D. in inorganic chemistry from the Pennsylvania State University, and was a Fellow at Harvard University. He is the author of 60+ publications and holds 40+ US and international patents. Dr. Neenan currently serves on the Board of Directors of Sun BioPharma Inc., a privately financed pancreatic oncology company, and as an advisor to Quad Technologies Inc., a development stage company specializing in cell and protein separations science.
GelTex: Investor Information
www.geltex.com, 27 Sept 2003 [cached]
Thomas X. Neenan, Ph.D. Vice President, Business Operations
Other People with the name "Neenan":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304